About U5 small nuclear ribonucleoprotein 40 kDa protein
U5 small nuclear ribonucleoprotein 40 kDa protein (SNRNP40) is a protein
from Homo sapiens identified by UniProt accession
Q96DI7, 357 residues long.
MolForge cross-references it against 0 known binders and
220 disease associations.
Target properties
| Protein name | U5 small nuclear ribonucleoprotein 40 kDa protein |
| UniProt accession | Q96DI7 |
| Gene | SNRNP40 |
| Organism | Homo sapiens |
| Length | 357 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (220)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.53
- cystatin C measurement · score 0.16
- hematocrit · score 0.07
- serum urea measurement · score 0.07
- Griscelli syndrome type 3 · score 0.07
- Griscelli disease · score 0.06
- isolated agammaglobulinemia · score 0.06
- common variable immunodeficiency · score 0.06
- T-B+ severe combined immunodeficiency due to JAK3 deficiency · score 0.06
- gamma chain deficiency · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96DI7-F1 | alphafold | PREDICTED | 85.26 | — |
Amino-acid sequence (357 residues)
MIEQQKRKGP ELPLVPVKRQ RHELLLGAGS GPGAGQQQAT PGALLQAGPP RCSSLQAPIM LLSGHEGEVY CCKFHPNGST LASAGFDRLI LLWNVYGDCD NYATLKGHSG AVMELHYNTD GSMLFSASTD KTVAVWDSET GERVKRLKGH TSFVNSCYPA RRGPQLVCTG SDDGTVKLWD IRKKAAIQTF QNTYQVLAVT FNDTSDQIIS GGIDNDIKVW DLRQNKLTYT MRGHADSVTG LSLSSEGSYL LSNAMDNTVR VWDVRPFAPK ERCVKIFQGN VHNFEKNLLR CSWSPDGSKI AAGSADRFVY VWDTTSRRIL YKLPGHAGSI NEVAFHPDEP IIISASSDKR LYMGEIQ
Explore U5 small nuclear ribonucleoprotein 40 kDa protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets